To do this, we evaluated the cytotoxic activity of commercially available PLK1 inhibitors (volasertib and onvansertib) as single agents in three mEOC cell lines (MCAS, EFO27, JHOM1) and found both drugs very active at nanomolar concentrations; similar cytotoxic effects were observed in non-mucinous ovarian cancer cells (Table 1). Here, PLK1 is linked to mucinous ovarian cancer.